This Cytokinetics Director Offered 5,000 Shares in November. Is It Time to Dump the Biopharmaceutical Inventory?

• Cytokinetics is a late-stage biopharmaceutical firm concentrating on muscle perform.

• Its inventory has gained nearly 30% this yr, besting the S&P 500.

• It just lately celebrated an enormous win in China, however authorized points at residence might threaten the inventory within the quick time period.

• These 10 shares might mint the subsequent wave of millionaires ›

B. Lynne Parshall, Director at Cytokinetics, Integrated (NASDAQ:CYTK), reported the sale of 5,000 shares in an open-market transaction valued at ~$323,650 on November 19, 2025; direct possession following the sale stands at 22,933 shares, in accordance with the SEC Kind 4 submitting.

Transaction worth based mostly on SEC Kind 4 reported worth ($64.73); post-transaction worth based mostly on Nov. 19, 2025 market shut ($64.79).

• How vital was this sale relative to B. Lynne Parshall’s remaining direct holdings?
  The disposition represented 17.9% of direct possession instantly previous to the transaction, with post-sale holdings at 22,933 shares.

• How does this transaction evaluate to the insider’s historic promoting sample?
  The sale of 5,000 shares matches the historic median sale measurement for B. Lynne Parshall, although the proportion of holdings bought per transaction has elevated because the share base has declined, reflecting lowered obtainable capability somewhat than elevated commerce measurement.

• What’s the present worth of the insider’s remaining direct place?
  Primarily based on the November 19, 2025 closing worth of $64.79, the post-transaction direct holding is valued at roughly $1.49 million.

• How does the transaction worth relate to Cytokinetics, Integrated’s one-year inventory efficiency?
  The ~$323,650 sale occurred with shares priced at $64.73, following a 27.36% complete return for the inventory over the previous 12 months as of the transaction date.

Word: 1-year efficiency calculated utilizing November nineteenth, 2025 because the reference date.

• Cytokinetics develops small molecule drug candidates concentrating on muscle perform, with a pipeline together with omecamtiv mecarbil (cardiac myosin activator), reldesemtiv (skeletal muscle troponin activator), aficamten (cardiac myosin inhibitor), and different early-stage property.

• The corporate operates a late-stage biopharmaceutical mannequin centered on drug discovery, scientific growth, and future commercialization, producing income primarily from strategic alliances and milestone funds.

• It targets healthcare suppliers and sufferers affected by coronary heart failure, neuromuscular, and uncommon muscle ailments, with a give attention to the U.S. and world biopharmaceutical markets.

Cytokinetics is a late-stage biotechnology firm specializing in muscle biology therapeutics for critical cardiovascular and neuromuscular ailments. The corporate leverages a differentiated pipeline of muscle activators and inhibitors, with a number of candidates in section 3 scientific trials. Its strategic give attention to innovation in muscle contractility positions it as a possible chief in addressing unmet medical wants in coronary heart failure and associated situations.

Parshall’s 5,000-share disposition got here after a large run-up within the biopharmaceutical firm’s share worth. The inventory has returned round 27% over the past yr, beating the S&P 500‘s 13% achieve.

The corporate continues to make information, just lately successful a $7.5 million milestone cost from Sanofi after China’s Nationwide Medical Merchandise Administration accepted Myqorzo for the therapy of adults with obstructive hypertrophic cardiomyopathy. Cytokinetics might obtain as much as $142.5 million extra, plus royalties, from the settlement with Sanofi, which holds unique rights to develop and commercialize the drug in China.

It additionally faces a Dec. 26 determination from the Meals and Drug Administration for the approval of aficamten, for sufferers with obstructive hypertrophic cardiomyopathy, or oHCM. It will be the corporate’s first FDA approval. This final level comes with some controversy, as the corporate faces a class-action lawsuit alleging Cytokinetics made “false and deceptive statements to the market” concerning the approval timeline for aficamten.

The inventory is more likely to be unstable as this information and approval performs out, making a inventory in an inherently dangerous sector even riskier.

Insider transaction: A commerce of firm securities by an government, director, or vital shareholder, reported to regulators.
Open-market transaction: The shopping for or promoting of securities on a public trade, not by personal or pre-arranged offers.
Direct possession: Shares held personally by an insider, not by trusts, funds, or oblique preparations.
Kind 4: A compulsory SEC submitting disclosing insider trades in an organization’s securities.
Milestone funds: Funds obtained when particular analysis, growth, or business targets are achieved, typically in biopharma partnerships.
Part III scientific trials: Late-stage research testing a drug’s security and effectiveness in massive affected person teams earlier than regulatory approval.
Whole return: The funding’s worth change plus all dividends and distributions, assuming these payouts are reinvested.
Biopharmaceutical: A sector centered on growing medication utilizing organic processes or molecules, typically for complicated ailments.
Cardiac myosin activator: A drug that will increase coronary heart muscle contraction energy by concentrating on the cardiac myosin protein.
Skeletal muscle troponin activator: A drug designed to boost skeletal muscle contraction by appearing on the troponin protein.
Cardiac myosin inhibitor: A drug that reduces coronary heart muscle contraction by inhibiting the cardiac myosin protein.
TTM: The 12-month interval ending with the latest quarterly report.

Ever really feel such as you missed the boat in shopping for probably the most profitable shares? Then you definately’ll wish to hear this.

On uncommon events, our knowledgeable workforce of analysts points a “Double Down” inventory advice for firms that they suppose are about to pop. Should you’re fearful you’ve already missed your likelihood to speculate, now’s the very best time to purchase earlier than it’s too late. And the numbers converse for themselves:

• Nvidia: if you happen to invested $1,000 once we doubled down in 2009, you’d have $451,671!*

• Apple: if you happen to invested $1,000 once we doubled down in 2008, you’d have $51,781!*

• Netflix: if you happen to invested $1,000 once we doubled down in 2004, you’d have $506,935!*

Proper now, we’re issuing “Double Down” alerts for 3 unbelievable firms, obtainable if you be part of Inventory Advisor, and there will not be one other likelihood like this anytime quickly.

See the three shares »

*Inventory Advisor returns as of December 15, 2025

Sarah Sidlow has no place in any of the shares talked about. The Motley Idiot has positions in and recommends Cytokinetics. The Motley Idiot has a disclosure coverage.

This Cytokinetics Director Offered 5,000 Shares in November. Is It Time to Dump the Biopharmaceutical Inventory? was initially printed by The Motley Idiot